Intelligence / Healthtech / New Clinical Trials / Txinno Bioscience Inc.
Txinno Bioscience Inc.
12 Nov 2026: Trial registered · Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLC. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 12 Nov 2026
- Title
- Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLC
- Conditions
- NSCLC (Non-small Cell Lung Cancer)
- Phase
- Phase 1, Phase 2
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- South Korea
- Country
- South Korea
- Reference
- NCT07933055
- Location
- South Korea
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Txinno Bioscience Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from South Korea
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.